Hydronidone Shows Significant Fibrosis Regression in Phase 3 Trial for CHB-Associated Liver Fibrosis

Gyre Therapeutics announced positive Phase 3 results for Hydronidone (F351) in treating liver fibrosis associated with chronic hepatitis B (CHB) in Ch...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Ct, Suite 450 Rockville, MD, 20850
info@pienomial.com
+91 9876543210
Copyright © 2025. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/Hydronidone Shows Significant Fibrosis Regression in Phase 3 Trial for CHB-Associated Liver Fibrosis